Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Angiomax Prescribers for ACS (US)(?)

Council Members in this Study Group: 32

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Howard Weintraub, MD
Clinical Director
NYU Medical Center

Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation...

Ramin Ebrahimi, MD
Director of Cardiac Catheterization Lab
Wadsworth VA Medical Center

Ramin Ebrahimi, MD, is an Associate Clinical Professor at the University of California, Los Angeles. He is also the Director of the Cardiac Catheterization Laboratory and Assistant Director of Nuclear Cardiology at the Wadsworth VA Medical Center. Dr. Ebrahimi’s clinical and research interests focus...

Samuel Butman, MD, Interventional Cardiologist, Verde Valley Heart LLCSamuel Butman, MD
Interventional Cardiologist
Verde Valley Heart LLC

Samuel Butman, MD, is an Interventional Cardiologist at Verde Valley Medical Center. Dr. Butman is also a Clinical Associate Professor of Medicine at University Medical Center in Tucson, Arizona. He has also served as the Director of Cardiology Interventional Fellows Program and Director of Cardiac...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Obvious answer - wrong question - NO IMPACT on prescribing | 05-19-2008
Author: GLG Expert Contributor

It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent.  It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.

Questions about bleeding, proper dose and appropriate patient subsets will limit use | 01-25-2008
Author: GLG Expert Contributor

TRITON-TIMI 38 study of 13,608 patients with ACS compared prasugrel against clopidogrel, combined with aspirin.  Prasugrel reduced the combined rate of CV death, MI or stroke (12.1% for clopidogrel vs. 9.9% for prasugrel). The benefit came at a cost of increased serious bleeding (1.4%, vs....

First Impressions Carry the Day and the Year -Vytorin Loses in ENHANCE | 01-17-2008
Analysis of: Schering releases ENHANCE data today | www.tradingmarkets.com
Author: Samuel Butman, MD, Interventional Cardiologist, Verde Valley Heart LLC

The reality that the actual details of the ENHANCE have not been circulated and that alternate explanations or caveats may be raised is probably unimportant.   The bottom line carries the day and the bottom line is that the trial's title, ENHANCE, was not achieved by the addition of VYTORIN when...

The impact on Vytorin and zetia sales will be modest reduction after the release of ENHANCE data | 01-14-2008
Analysis of: Schering releases ENHANCE data today | www.tradingmarkets.com
Author: GLG Expert Contributor

Physicians have several possible conclusions that can be taken; These include: - the trial is flawed - the selection of patients with much less CIMT than previous trials such as ASAP and ARBITER flaws the study -  the failure to meet the trial endpoint is only a surrogate and clinical trial data...

Risk Versus Benefit | 11-23-2007
Author: Ramin Ebrahimi, MD, Director of Cardiac Catheterization Lab, Wadsworth VA Medical Center

The pooled analysis of Rimonabant trials point to a significant increase in psychiatric disorders. These studies also point to significant improvements in markers of cardiovascular risk. Risks versus benefits must be considered before the final decision is made on this class of medications.

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Other Freestanding Healthcare Facility
  • Academic Institution*
  • Contract Research Organization, Independent/Small
  • Integrated Healthcare Delivery Network (IDN)

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Director
  • Medical Director
  • Vice President
  • Principal
  • Owner
  • Physician - Division Head

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-09-05T09:45:16.717